Tag - PRR

By Len Zehr After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its...